Regimen | Target | RR | PFS | OS | Reference |
---|---|---|---|---|---|
% | mo | mo | |||
PCSC targeting | |||||
Vantictumab | WNT | 53.0 | 7.2 | — | Messersmith et al., 2016 |
Ipafricept | WNT | 29.0 | 3.9 | — | Weekes et al., 2016 |
Tarextumab | Notch 2/3 | 19.1 vs. 31.8 | 3.7 vs. 5.5 | 6.4 vs. 7.9 | O’Reilly et al., 2017 |
Vismodegib | SMO | 43.0 | 5.5 | 10 | Jesus-Acosta et al., 2014 |
Sonidegib | SMO | 39.0 | — | — | Lee et al., 2017 |
VERSUS-4718 | FAK | — | — | — | |
Kinase or signaling pathway targeting | |||||
LCL161 | Apoptosis proteins | — | — | — | |
Istiratumab | IGF-1R/ErbB3 | — | — | — | Ko et al., 2016b |
Erlotinib | EGFR | 46 | 5.3 | 9.3 | Leichman et al., 2012 |
Aptorsen | HSP27 (NF-κB) | 18.0 vs. 18.0 | 2.7 vs. 3.8 | 5.3 vs. 6.9 | Ko et al., 2017 |
Momelotinib | JAK | 28 | — | — | Ng et al., 2019 |
Itacitinib | JAK | 24 | — | — | Beatty et al., 2018 |
Other targets | |||||
PEGPH20 | HA | 45.0 vs. 31.0 | 11.5 vs. 8.5 | — | Hingorani et al., 2018 |
Evofosfamide | DNA (hypoxia-activated) | 53.0 | — | — | Borad et al., 2016 |
ErbB3, receptor tyrosine-protein kinase (also known as human epidermal growth factor receptor 3); EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; HA, hyaluronic acid; HSP27, heat shock protein 27 (also known as heat shock protein beta-1); IGF-1R, insulin-like growth factor 1 receptor; JAK, Janus kinase; NF-κB, nuclear factor kappa B; Notch 2/3, neurogenic locus notch homolog protein 2/3; SMO, smoothened; WNT, wingless-related integration site; —, no data available.